Glutamine

Glutamine

SCHEMBL411588

[15NH2]C(=O)CCC([15NH2])C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 1.00
ALOX15 P16050 1/20 1.00
BLM P54132 1/20 1.00
PMP22 Q01453 1/20 1.00
GSR P00390 2/20 0.68
CYP1A2 P05177 2/20 0.68
GRM8 O00222 2/20 0.68
GRM6 O15303 2/20 0.68
GRM7 Q14831 2/20 0.68
GRM4 Q14833 2/20 0.68
GRIN2D O15399 1/20 0.68
GRIN3B O60391 1/20 0.68
GRIK1 P39086 1/20 0.68
GRM5 P41594 1/20 0.68
GRIA1 P42261 1/20 0.68
GRIA2 P42262 1/20 0.68
GRIA3 P42263 1/20 0.68
SLC1A3 P43003 1/20 0.68
SLC1A2 P43004 1/20 0.68
SLC1A1 P43005 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutamine SCHEMBL31436292 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL711605 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL7452 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL411575 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL411170 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL5580393 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL7453 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL994966 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL1332116 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL31619675 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120064004-A1 ISOTOPOLOGUES OF THALIDOMIDE CELGENE CORPORATION 2012-03-15 US disclosed
US-20120053159-A1 ISOTOPOLOGUES OF LENALIDOMIDE CELGENE CORPORATION 2012-03-01 US disclosed
US-20100297609-A1 VIVO ISOTOPIC LABELING METHOD FOR QUANTITATIVE GLYCOMICS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053159-A1 ISOTOPOLOGUES OF LENALIDOMIDE CDK4, SRMS, DAP3 KMT2A 1463/4885ALOX15 3394/4885BLM 1570/4885
US-20120064004-A1 ISOTOPOLOGUES OF THALIDOMIDE CDK4, FKBP8, FKBP1A KMT2A 1417/4885ALOX15 4164/4885BLM 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.